- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Califano on MARIPOSA-2 Outcomes by Baseline Resistance Mechanisms in EGFR+ NSCLC
May 31st 2025, 7:26pm
Raffaele Califano, MD, discusses molecularly stratified outcomes amivantamab with chemotherapy vs chemotherapy alone in patients with advanced EGFR-mutant NSCLC.
Dr Chahoud on Early Efficacy With Zanzalintinib Plus Nivolumab With/Without Relatlimab in ccRCC
May 31st 2025, 7:17pm
Jad Chahoud, MD, MPH, MHA, shares early-phase data with zanzalintinib plus nivolumab with or without relatlimab-rmbw in previously untreated ccRCC.
Long-Term Data Underscore Role of Zanubrutinib in Treatment-Naive CLL/SLL With 17p Deletions
May 31st 2025, 6:24pm
Zanubrutinib retained long-term efficacy as a frontline treatment in CLL/SLL harboring 17p deletions.
Sotorasib/Panitumumab Resistance May Be Linked to Genomic Alterations in KRAS G12C+ mCRC
May 31st 2025, 4:20pm
Treatment resistance to sotorasib plus panitumumab may stem from genomic alterations in KRAS G12C–mutated CRC.
Nivolumab Plus Ipilimumab Shows Sustained PFS Benefit in MSI-H/dMMR mCRC
May 31st 2025, 3:15pm
Nivolumab plus ipilimumab displayed superior PFS and PFS2 data vs chemotherapy and nivolumab monotherapy in mismatch repair-deficient colorectal cancer.
Frontline Anlotinib Plus CapeOX Elicits Similar Efficacy to SOC Therapy in RAS/BRAF Wild-Type mCRC
May 31st 2025, 2:41pm
Anlotinib/chemotherapy demonstrated similar responses and PFS outcomes vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type mCRC.
ctDNA-Guided Chemo Does Not Yield RFS Benefit in Stage III Colon Cancer
May 31st 2025, 2:20pm
Adjuvant chemotherapy decisions based on ctDNA status did not improve recurrence-free survival in stage III colon cancer.
T-DXd Represents a New SOC in Second-Line HER2+ Gastric/GEJ Cancer
May 31st 2025, 12:00pm
T-DXd demonstrated clinically meaningful antitumor responses as second-line treatment in HER2-positive gastric/GEJ cancer.
Vepdegestrant Improves PFS in ESR1-Mutant ER+/HER2– Advanced Breast Cancer
May 31st 2025, 12:00pm
PFS was improved when patients with ESR1-mutant ER-positive, HER2-negative advanced breast cancer received treatment with vepdegestrant vs fulvestrant.
ASCENT-04 Data Support Sacituzumab Govitecan Plus Pembrolizumab as New SOC in PD-L1+ TNBC
May 31st 2025, 12:00pm
Frontline sacituzumab govitecan plus pembrolizumab improved PFS vs chemotherapy plus pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.
Adjuvant Chemotherapy Improves DFS in Molecularly Higher-Risk NSCLC
May 31st 2025, 12:00pm
Adjuvant chemotherapy generated a DFS benefit over observation in patients identified as having higher-risk nonsquamous NSCLC per a prognostic assay.
KITE-363 Elicits Responses With Acceptable Tolerability in R/R B-Cell Lymphoma
May 30th 2025, 11:42pm
Phase 1 data indicate that KITE-363 represents a promising therapeutic approach for patients with relapsed/refractory B-cell lymphoma.
T-DXd Rechallenge Is Safe After Grade 1 ILD in Breast Cancer and Other Solid Tumors
May 30th 2025, 11:25pm
A high rate of patients with breast cancer and other solid tumors were rechallenged with trastuzumab deruxtecan after grade 1 interstitial lung disease.
Dr Strickler on the Efficacy of Sotorasib Plus Panitumumab/Chemo in KRAS G12C+ mCRC
May 30th 2025, 11:11pm
John H. Strickler, MD, discusses the preliminary efficacy of sotorasib in combination with multiple agents across tumor types harboring KRAS G12C mutations.
ctDNA-Based MRD Provides Prognostic Value for First-Line Treatment in DLBCL
May 30th 2025, 11:10pm
PhasED-Seq–assessed ctDNA-based MRD negativity was strongly associated with improved PFS after frontline treatment in patients with DLBCL.
OncLive Polls Show Top Votes for Anticipated Gynecologic Cancer Abstracts at ASCO 2025
May 30th 2025, 1:00pm
Experts from the gynecologic oncology space vote on their most anticipated abstracts on OncLive’s social media.
Encorafenib/Cetuximab Plus Chemo Boosts PFS in BRAF V600E+ mCRC
May 30th 2025, 12:00pm
Encorafenib plus cetuximab and mFOLFOX6 improved progression-free survival in BRAF V600E–mutated metastatic colorectal cancer.
Looking Ahead For the Treatments of R/R MM
May 29th 2025, 12:05pm
Unpacking Key Data from ASH 2024
Panelists discuss how health care professionals can prepare for emerging trends in treating relapsed/refractory multiple myeloma (R/R MM) by staying informed on innovative therapies and adapting to evolving patient care strategies.
Looking Into the Future of AML Treatments
May 29th 2025, 12:00pm
Unpacking Key Data from ASH 2024
Panelists discuss how health care professionals can prepare for emerging trends in acute myeloid leukemia (AML) treatments by exploring advancements in diagnostics, targeted therapies, and personalized medicine.
Real-World Analysis Informs Future Directions for Evaluating Dostarlimab/Chemotherapy in Advanced Endometrial Cancer
May 28th 2025, 2:08pm
Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.